Massive human rivaroxaban overdose

Thomas Lehmann; Katharina E. Hofer; Michael Baumann; Karin Hasler; Alessandro Ceschi; Hugo Kupferschmidt; Gabriele Rohde; Wolfgang Korte

doi:10.1160/TH14-02-0138

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 112(04): 834-836
DOI: 10.1160/TH14-02-0138

Letters to the Editor

Schattauer GmbH

Massive human rivaroxaban overdose

Thomas Lehmann

¹Center of Laboratory Medicine and Hemostasis and Hemophilia Center St. Gallen, St. Gallen, Switzerland

,

Katharina E. Hofer

²Swiss Toxicological Information Centre, Associated Institute of the Zurich University, Zurich, Switzerland

,

Michael Baumann

¹Center of Laboratory Medicine and Hemostasis and Hemophilia Center St. Gallen, St. Gallen, Switzerland

,

Karin Hasler

³Department of Emergency, Kantonsspital St. Gallen, Switzerland

,

Alessandro Ceschi

²Swiss Toxicological Information Centre, Associated Institute of the Zurich University, Zurich, Switzerland

,

Hugo Kupferschmidt

²Swiss Toxicological Information Centre, Associated Institute of the Zurich University, Zurich, Switzerland

,

Gabriele Rohde

⁴Bioanalytik, Bayer Pharma AG, Leverkusen, Germany

,

Wolfgang Korte

¹Center of Laboratory Medicine and Hemostasis and Hemophilia Center St. Gallen, St. Gallen, Switzerland

› Author Affiliations

Abstract

Full Text

References

References
1 Patel MR, Mahaffey KW, Garg J. et al. ROCKETAF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
2 Bauersachs R, Berkowitz SD, Brenner B. et al. Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
3 Eriksson BI, Borris LC, Friedman RJ. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
4 Eisenberg PR, Siegel JE, Abendschein DR. et al. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-1883.
5 Perzborn E, Strassburger J, Wilmen A. et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-521.
6 Bayer Pharma AG. Xarelto (rivaroxaban) summary of product characteristics. 2013.
7 Kubitza D, Becka M, Voith B. et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
8 Mueck W, Becka M, Kubitza D. et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban- an oral, direct factor Xa inhibitor- in healthy subjects. Int J Clin Pharmacol Ther 2007; 45: 335-344.
9 Asmis LM, Alberio L, Angelillo-Scherrer A. et al. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012; 129: 492-498.
10 Samama MM, Martinoli JL, LeFlem L. Assessment of laboratory assays to measure rivaroxaban- an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
11 Barrett YC, Wang Z, Frost C. et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271.
12 Mueck W, Eriksson BI, Bauer KA. et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban- an oral, direct Factor Xa inhibitor- in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-216.
13 Eerenberg SE, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban an dabigatran by prothrombin complex concentrate: A randomized placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
14 Zhou W, Zorn M, Nawroth P. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44: 771-778.
15 Dowlatshahi D, Butcher KS, Asdaghi N. et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 1012; 43: 1812-1817.
16 Chyka PA, Seger D, Krenzelok EP. et al. Single-dose activated charcoal. Clin Toxicol 2005; 43: 61-87.